Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. director Dennis M. Nally reported a charitable stock gift. On 12/17/2025, he made a bona fide gift of 1,173 shares of Cencora common stock, recorded at a price of $0 per share, to a charitable donor advised fund.
After this transaction, Nally beneficially owns 12,304 shares of Cencora common stock in direct ownership. The filing reflects a personal charitable transfer rather than an open-market sale.
An insider of COR has filed a notice of intent to sell 1,677 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/19/2025. The shares have an aggregate market value of 578565.00, compared with 193,993,444 shares of the same class stated as outstanding. These shares were acquired on 11/10/2024 via restricted stock vesting from the issuer as compensation. The seller represents that they are not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Shareholder Robert P. Mauch has filed a notice to sell 5,096 shares of the issuer’s common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of December 18, 2025 and an aggregate market value of $1,750,221.20. The notice states that 193,993,444 shares of this class are outstanding. The shares to be sold were acquired from the issuer through restricted stock vesting in November 2024 (773 and 560 shares) and the exercise of stock options granted in November 2019 for 3,763 shares.
The filing also discloses that over the prior three months Mauch sold additional common shares in three transactions of 5,097, 5,097, and 5,096 shares, with gross proceeds ranging from $1,478,130.00 to $1,868,397.44.
Cencora, Inc. President & CEO and director Robert P. Mauch reported equity transactions dated 12/15/2025. He acquired 638 shares of common stock in a transaction coded “M” related to restricted stock units and then disposed of 638 shares in a transaction coded “F” at a price of $350.32 per share to cover FICA and associated income taxes on a 2025 restricted stock unit grant. The $350.32 price was the closing price of the company’s common stock on 12/15/2025 used to calculate this tax obligation. After these transactions, he beneficially owned 69,392 shares of common stock directly and 15,322 restricted stock units, including a 638-unit grant that vests in three equal installments on 11/12/2026, 11/12/2027 and 11/12/2028.
Cencora, Inc.'s chief financial officer reported equity compensation activity involving restricted stock units and related tax withholding. On 12/15/2025, 199 shares of common stock were acquired in connection with restricted stock units, and 199 shares were then withheld to satisfy FICA and associated income tax obligations on a 2025 restricted stock unit grant, using a share price of $350.32.
After these transactions, the officer directly held 134,941.3479 shares of common stock and 4,534 restricted stock units. The restricted stock units referenced in the filing vest in three equal installments on 11/12/2026, 11/12/2027 and 11/12/2028.
Cencora, Inc. senior vice president and chief accounting officer Lazarus Krikorian reported insider equity activity dated
A holder of COR common stock has filed a Rule 144 notice to sell 4031 shares on the NYSE, with an aggregate market value of $1383580.29, out of 193993444 shares of this class outstanding.
The shares were acquired through restricted stock vesting from the issuer as compensation on four dates in 2025, in amounts of 1375, 1032, 1022, and 602 shares, with payment recorded on the same dates. The planned sale date is approximately December 17, 2025, through Fidelity Brokerage Services LLC. The person signing the notice represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Cencora, Inc. plans to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology from TPG and other shareholders. OneOncology is described as a physician-led national platform supporting independent oncology-focused medical specialty practices. Cencora will pay approximately $3.6 billion for these equity interests and retire $1.3 billion of OneOncology’s existing corporate debt, for total cash consideration of about $5.0 billion.
The company expects to fund the transaction with new debt financing and has obtained $4.5 billion in bridge financing commitments. OneOncology’s affiliated practices and management will retain a minority ownership interest, and completion of the deal is subject to customary closing conditions, including receipt of required regulatory approvals.
Cencora, Inc. is a large global pharmaceutical sourcing and distribution company serving healthcare providers and drug manufacturers across human and animal health. It distributes branded, specialty, and generic drugs and provides services such as data analytics, reimbursement support, logistics, pharmacy management, and packaging.
In fiscal 2025, the company continued to execute a strategy focused on its core U.S. and international distribution businesses while expanding higher-margin manufacturer services. Cencora acquired an 85% stake in Retina Consultants of America for
Customer concentration is significant: Walgreens and Boots generated about
Cencora, Inc. (COR) President & CEO reports RSU activity. Director and executive Robert P. Mauch reported the vesting and conversion of 5,790 restricted stock units into common stock on 11/20/2025. These restricted stock units were granted for no cash consideration and are scheduled to vest in three equal installments on 11/20/2025, 11/20/2026 and 11/20/2027.
To cover tax withholding related to the vesting, 2,144 shares of common stock were disposed of at a price of $362.07 per share. After these transactions, Mauch beneficially owns 69,392 shares of Cencora common stock directly.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
